← Back to Search

Cognitive Bias Modification for Obsessive-Compulsive Disorder

N/A
Recruiting
Research Sponsored by Mclean Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 0, 1, 2, 3, and 4
Awards & highlights

Study Summary

This trial will examine if CBM-I or AAT is an effective addition to treatment as usual for OCD and related disorders.

Who is the study for?
This trial is for adults with OCD or related disorders currently receiving treatment at the McLean Hospital OCD Institute. Participants must consent to the main study protocol and meet specific criteria, like scoring high on certain scales that measure obsessive beliefs and contamination fears.Check my eligibility
What is being tested?
The study tests Cognitive Bias Modification for Interpretation (CBM-I) and Approach Avoidance Training (AAT), which are computerized tasks aimed at changing negative thought patterns and reactions to feared stimuli in people with OCD. It compares these methods against psychoeducation and a sham training.See study design
What are the potential side effects?
Since CBM-I, AAT, psychoeducation, and sham training are non-invasive psychological interventions primarily involving computer tasks, they typically do not have physical side effects. However, participants may experience temporary increases in anxiety or discomfort.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 0, 1, 2, 3, and 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 0, 1, 2, 3, and 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Average Score on Obsessive Beliefs Questionnaire
Secondary outcome measures
Change in Average Score on Behavioral Inhibition/Behavioral Activation Scales
Change in Average Score on Depressive Symptom Index Suicidality Subscale. There are 4 items scored from 0-3 with greater numbers indicating greater severity.
Change in Average Score on Yale-Brown Obsessive Compulsive Scale
+6 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Cognitive bias modification with treatment as usualExperimental Treatment1 Intervention
Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
Group II: Approach avoidance training with treatment as usualExperimental Treatment1 Intervention
Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
Group III: Psychoeducation with treatment as usualPlacebo Group1 Intervention
Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
Group IV: Inactive sham approach avoidance trainingPlacebo Group1 Intervention
Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training

Find a Location

Who is running the clinical trial?

Mclean HospitalLead Sponsor
213 Previous Clinical Trials
21,594 Total Patients Enrolled
9 Trials studying Obsessive-Compulsive Disorder
643 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Approach avoidance training Clinical Trial Eligibility Overview. Trial Name: NCT03799419 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Psychoeducation with treatment as usual, Cognitive bias modification with treatment as usual, Inactive sham approach avoidance training, Approach avoidance training with treatment as usual
Obsessive-Compulsive Disorder Clinical Trial 2023: Approach avoidance training Highlights & Side Effects. Trial Name: NCT03799419 — N/A
Approach avoidance training 2023 Treatment Timeline for Medical Study. Trial Name: NCT03799419 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Sep 2024